

- **Full Name:** Moon Ki Choi
 - **Current Position & Affiliation:** Clinical professor, National Cancer Center
 - **Country:** Republic of Korea
-

- **Educational Background:**

- 2018, PhD, Graduate School, Sungkyunkwan University, Seoul, Korea
- 2013, MS, Graduate School, Sungkyunkwan University, Seoul, Korea
- 2004, MD, Sungkyunkwan University, Seoul, Korea

- **Professional Experience:**

- 2017 – Present, Clinical professor, Center for Colorectal cancer, National Cancer Center, Goyang, Korea
- 2015 – 2017, Clinical assistant professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea
- 2012 – 2014, Fellowship, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea
- 2005 – 2009, Residentsip, Department of Medicine, Samsung Medical Center, Seoul, Korea
- 2004 – 2005, Internship, Samsung Medical Center, Seoul, Korea

- **Professional Organizations:**

- American Society of Clinical Oncology
- Korean Society of Medical Oncology
- The Korean Association of Internal Medicine

- **Main Scientific Publications:**

1. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O⁶-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02.
Oh CR, Kim JE, Lee JS, Kim SY, Kim TW, Choi J, Kim J, Park IJ, Lim SB, Park JH, Kim JH, **Choi MK**, Cha Y, Baek JY, Beom SH, Hong YS. Clin Oncol (R Coll Radiol). 2023;35(2):e143-e152
2. Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study.
Choi MK, Cha Y, Baek JY. Oncology. 2021;99(10):665-672.
3. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy.
Kim SH, **Choi MK**, Park NY, Hyun JW, Lee MY, Kim HJ, Jung SK, Cha Y. Sci Rep. 2020;10(1):7995.

4. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y, Kim SY, Yeo HY, Baek JY, **Choi MK**, Jung KH, Dong SM, Chang HJ. Neoplasia. 2019;21(1):146-155.

5. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM, **Choi MK**, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. PLoS One. 2018;13(4):e0194730.